02.15.19
Burt’s Bees reports that the Journal of Drugs in Dermatology has published clinical data supporting the efficacy and tolerability of its skin care products as an adjunct to rosacea prescription therapy. Abstracts outlining the study data will be shared at the American Academy of Dermatology Annual Meeting next month in Washington, D.C.
The nature-based regimen clinically and statistically improved investigator-rated redness (erythema) by 28%; spider veins (telangiectasia) by 26% and pimple-like skin lesions (papules/pustules) by 34% (p<0.001) whereas a control synthetic regimen improved rosacea symptoms by 8 to 12%. Differences between treatments were statistically significant. Overall skin appearance measured by the investigator was clinically and statistically improved from baseline by 32% and 12% with the nature-based regimen and control regimens, respectively. No clinically significant tolerability issues were reported for either regimen at week four.
“Rosacea can be a difficult condition to manage representing an important subset of sensitive skin. Carefully designed cleansers and moisturizers are important to maximize treatment results,” said Zoe Draelos, MD, president, Dermatology Consulting Services, PLLC, High Point, NC, the study’s principal investigator. “The data suggest that products made with nature-based ingredients can be effective when used in conjunction with prescription therapies.”
This ten-week, single-site controlled, product-blinded study was conducted in 80 women with Fitzpatrick skin types I-III and facial rosacea requiring prescription medication. After baseline measurements, subjects received six weeks of 0.75% metronidazole gel and were randomized to receive the nature-based regimen or control regimen, twice daily for four weeks.
“These data support the whole formula regimen of natural origin in the management of dermatologic conditions, such as rosacea, that require prescription medication” said Hemali Gunt, PhD, head of clinical and scientific affairs, at Burt’s Bees. “This work further affirms our innovations in whole formulas, designed to provide functional ingredients to restore and protect the skin, is ideal for patients who seek an alternative to conventional skin care products for the management of rosacea.”
Burt’s Bees, which is part of Clorox, will present three abstracts featuring trial data at the meeting, which is scheduled for March 1-5.
The nature-based regimen clinically and statistically improved investigator-rated redness (erythema) by 28%; spider veins (telangiectasia) by 26% and pimple-like skin lesions (papules/pustules) by 34% (p<0.001) whereas a control synthetic regimen improved rosacea symptoms by 8 to 12%. Differences between treatments were statistically significant. Overall skin appearance measured by the investigator was clinically and statistically improved from baseline by 32% and 12% with the nature-based regimen and control regimens, respectively. No clinically significant tolerability issues were reported for either regimen at week four.
“Rosacea can be a difficult condition to manage representing an important subset of sensitive skin. Carefully designed cleansers and moisturizers are important to maximize treatment results,” said Zoe Draelos, MD, president, Dermatology Consulting Services, PLLC, High Point, NC, the study’s principal investigator. “The data suggest that products made with nature-based ingredients can be effective when used in conjunction with prescription therapies.”
This ten-week, single-site controlled, product-blinded study was conducted in 80 women with Fitzpatrick skin types I-III and facial rosacea requiring prescription medication. After baseline measurements, subjects received six weeks of 0.75% metronidazole gel and were randomized to receive the nature-based regimen or control regimen, twice daily for four weeks.
“These data support the whole formula regimen of natural origin in the management of dermatologic conditions, such as rosacea, that require prescription medication” said Hemali Gunt, PhD, head of clinical and scientific affairs, at Burt’s Bees. “This work further affirms our innovations in whole formulas, designed to provide functional ingredients to restore and protect the skin, is ideal for patients who seek an alternative to conventional skin care products for the management of rosacea.”
Burt’s Bees, which is part of Clorox, will present three abstracts featuring trial data at the meeting, which is scheduled for March 1-5.